Harmony Biosciences shareholders elect directors, ratify auditors, approve executive compensation at 2023 annual meeting

Proposal 3. The approval on a non-binding, advisory basis, of the compensation of the Company’s named executive officers as described in our proxy materials. ​ ​ ​ ​ ​ ​ ​ ​ ​ Votes For Votes Against Abstain Broker Non-Votes 51,543,958 1,252,960 406,969 463,671 ​ Based on the votes set forth above, the compensation of the Company’s named executive officers has been approved.

Proposal 1. The election of the three Class II directors listed below to serve until the Company’s 2026 annual meeting of stockholders and until their successors are duly elected and qualified. ​ ​ ​ ​ ​ ​ Votes For Withheld Broker Non-Votes Antonio Gracias 41,295,494 11,908,393 463,671 Jack Bech Nielsen 38,571,010 14,632,877 463,671 Andreas Wicki, Ph.D 37,229,122 15,974,765 463,671 ​ Based on the votes set forth above, each of the director nominees was duly elected.

Proposal 2. The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. ​ ​ ​ ​ ​ ​ ​ Votes For Votes Against Abstain 53,633,333 25,629 8,596 ​ Based on the votes set forth above, the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was duly ratified.